GLPwatch
Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN-6 trial.
Diabetes Obes Metab · 2023
Last updated 2026-05-28| Journal | Diabetes Obes Metab, 2023 |
|---|---|
| Citations | 2 |
| Relative citation ratio | 0.26 |
| NIH percentile | 17 |
| Molecules | semaglutide |
| Conditions studied | Type 2 Diabetes, Cardiovascular Risk Reduction |
Full record and abstract on PubMed 36514266 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.